Viewing Study NCT06362278



Ignite Creation Date: 2024-05-06 @ 8:24 PM
Last Modification Date: 2024-10-26 @ 3:26 PM
Study NCT ID: NCT06362278
Status: RECRUITING
Last Update Posted: 2024-04-12
First Post: 2024-01-05

Brief Title: A Multi-omics Study of Healthy Premature CAD Patients
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Organization: The First Affiliated Hospital with Nanjing Medical University

Study Overview

Official Title: A Multi-omics Study of Patients With Premature Coronary Artery Disease in the Absence of Common Risk Factors
Status: RECRUITING
Status Verified Date: 2024-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The goal of this multi-center observational clinical trial is to investigate the genetic risk factors of patients with premature CAD and none traditional CAD risk factors through a multi-omics approach

The main questions it aims to answer are

Genetic risk factors metabolic fingerprints of patients with premature CAD and none traditional CAD risk factors remain unknown
How to optimize current primary prevention strategy for this rare CAD subgroup
Detailed Description: Cardiovascular diseases CVDs remain the leading cause of global mortality despite continuous efforts in disease prevention and treatment optimization In 2022 alone CVD caused an estimated 198 million deaths worldwide and ischemic heart disease had the highest global age-standardized DALYs of all diseases at 22759 per 100000 Therefore research on the etiology and pathogenesis of coronary artery disease CAD remains first priority

It is now widely known that risk factors such as diabetes mellitus hyperlipidemia hypertension smoking and obesity are closely related to CAD but they only explain 30-40 of CAD risk factors and large-sample cohort and twin studies have concluded that CAD heritability is estimated to be 40 to 60 With the development of the Human Genome Project and high-throughput sequencing technology in the past decade increasingly larger genome-wide association studies GWAS have been conducted worldwide and biobanks established Public sequencing data is increasingly being used as external common controls instead of sequencing new controls in every study Till now thousands of mutations related to CAD have been identified Multiple Polygenic risk scores PRSs have been developed to improve the prediction of common complex cardiovascular diseases like CAD on individual level

Premature CAD has been proved to have strong link with family history of cardiovascular and cerebral vascular disease which indicates a strong genetic background of premature CAD However there is an even more scarce inconspicuous subgroup of premature CAD defined as premature CAD without common CAD risk factors in this study First of all most of those patients were considered healthy or at very low risk of CVDs before CAD was diagnosed secondly genetic risk factors metabolic fingerprints of such patients remain unknown thirdly we still dont know yet how to optimize current primary prevention strategy for this rare CAD subgroup

For this regard we designed this multi-omics study to cover the questions mentioned above

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None